OncoMatch/Clinical Trials/NCT06056752
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Is NCT06056752 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including QH103 Cell and Fludarabine for b-cell acute lymphoblastic leukemia.
Treatment: QH103 Cell · Fludarabine · Cyclophosphamide — This is a single-arm, single-center, interventional, dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immune cell therapy
Cannot have received: donor lymphocyte infusion
Lab requirements
Kidney function
serum creatinine≤1.5 × upper limit of normal range (uln)
Liver function
glutamine aminotransferase, aspartate aminotransferase ≤3 times uln, total bilirubin ≤1.5 times uln
Cardiac function
left ventricular ejection fraction ≥50% on echocardiography
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify